Comparative Pharmacology
Head-to-head clinical analysis: CALCIBIND versus PHOSLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CALCIBIND versus PHOSLO.
CALCIBIND vs PHOSLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CALCIBIND (sodium polystyrene sulfonate) is a cation-exchange resin that exchanges sodium ions for potassium ions in the gastrointestinal tract, primarily in the colon, thereby reducing serum potassium levels.
Calcium acetate binds phosphate in the gastrointestinal tract, forming insoluble calcium phosphate that is excreted in feces, thereby reducing serum phosphate levels.
5 mg orally once daily, taken without food or with a low-fat meal.
667 mg (two 667-mg tablets or one 667-mg capsule) orally three times daily with meals, titrated to maintain serum phosphate between 3.5-5.5 mg/dL; maximum 4000 mg/day.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours in patients with normal renal function; prolonged to 12-24 hours in severe renal impairment (eGFR <30 mL/min), necessitating dose adjustment.
Not applicable; minimal systemic absorption, local gastrointestinal action
Primarily renal (90% as unchanged drug via glomerular filtration and tubular secretion). Biliary/fecal: 10% (unabsorbed drug and metabolites).
Primarily fecal as unabsorbed drug; minimal renal elimination (<0.5%)
Category C
Category C
Phosphate Binder
Phosphate Binder